Adenomyosis: clinical aspects, impact on fertility and pregnancy outcome

Cover Page


Aim. To investigate the modern condition of the problem of adenomyosis and its impact on women’s reproductive function.

Material and methods. The article presents a systematic literature review on the results of research search in electronic databases MEDLINE, PubMed, EMBASE, Cochrane Library and Elibrary.

Results. Adenomyosis is a common but insufficiently studied disease. Modern imaging methods, such as transvaginal ultrasound and MRI, make it possible to diagnose adenomyosis at the early stages of the disease and perform the organ-preserving surgery. A medical treatment of adenomyosis requires to develop a lifelong management plan, the choice depends on the woman’s age, reproductive status and clinical symptoms. Currently, there is evidence of a negative impact of adenomyosis on fertility and pregnancy outcomes. Dienogest, a 19-norsteroid derivative, is a progestin with high selectivity to progesterone receptors, it exerts a hypogonadotropic effect and an antiproliferative effect on the endometrium. A mild regime of supression of ovarian function provides adequate conditions for blood supply to the uterus before planning a pregnancy. The immunomodulating effect of progestin may be useful for implantation and fetal protection to pregnancies occurring after treatment. Dienogest treatment increases the effectiveness of IVF cycles for adenomyosis of varying severity.

Conclusion. The review summarizes the aspects of prevalence, comorbidity, risk factors, classification, mechanism of pathogenesis, clinical manifestations, diagnosis, treatment of adenomyosis, impact on fertility and pregnancy outcomes.

Full Text

Restricted Access

About the authors

Rushania I. Gabidullina

Kazan State Medical University

Author for correspondence.
ORCID iD: 0000-0002-7567-6043

Russian Federation, Kazan

D. Sci. (Med.), Prof, Kazan State Medical University

Angelina I. Kuptsova

Kazan State Medical University

ORCID iD: 0000-0002-4914-5206

Russian Federation, Kazan

Resident, Kazan State Medical University

Ekaterina A. Koshelnikova

City Clinical Hospital №7

ORCID iD: 0000-0003-3635-8963

Russian Federation, Kazan

gynecologist, City Clinical Hospital №7

Fikret R. Nuhbala

Kazan State Medical University

ORCID iD: 0000-0002-1244-7577

Russian Federation, Kazan

Graduate Student, Kazan State Medical University

Rufat R. Bagirli

Kazan State Medical University

ORCID iD: 0000-0002-0211-3872

Russian Federation, Kazan

Graduate Student, Kazan State Medical University

Elmira R. Mingaleva

Kazan State Medical University

ORCID iD: 0000-0002-6711-9079

Russian Federation, Kazan

Student, Kazan State Medical University

Endzhe A. Khaliullina

Kazan State Medical University

ORCID iD: 0000-0002-3675-6841

Russian Federation, Kazan

Student, Kazan State Medical University


  1. Tan J, Yong P, Bedaiwy MA. A critical review of recent advances in the diagnosis, classification, and management of uterine adenomyosis. Curr Opin Obstet Gynecol 2019; 31 (4): 212–21. doi: 10.1097/GCO.0000000000000555
  2. Gordts S, Grimbizis G, Campo R. Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. Fertil Steril 2018; 109 (3): 380–8.e1. doi: 10.1016/j.fertnstert.2018.01.006
  3. Aleksandrovych V, Basta P, Gil K. Current facts constituting an understanding of the nature of adenomyosis. Adv Clin Exp Med 2019; 28 (6): 839–46. doi: 10.17219/acem/79176
  4. Donnez J, Donnez O, Dolmans MM. Introduction: Uterine adenomyosis, another enigmatic disease of our time. Fertil Steril 2018; 109 (3): 369–70. doi: 10.1016/j.fertnstert.2018.01.035
  5. Templeman C, Marshall SF, Ursin G et al. Adenomyosis and endometriosis in the California Teachers Study. Fertil Steril 2008; 90: 415–24. doi: 10.1016/j.fertnstert.2007.06.027
  6. Riggs JC, Lim EK, Liang D, Bullwinkel R. Cesarean section as a risk factor for the development of adenomyosis uteri. J Reprod Med 2014; 59: 20–4.
  7. García-Solares J, Donnez J, Donnez O, Dolmans MM. Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril 2018; 109 (3): 371–9. doi: 10.1016/j.fertnstert.2017.12.030
  8. Varras M, Polyzos D, Akrivis C. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003; 24: 258–68.
  9. Parazzini F, Mais V, Cipriani S et al. Determinants of adenomyosis in women who underwent hysterectomy for benign gynecological conditions: results from a prospective multicentric study in Italy. Eur J Obstet Gynecol Reprod Biol 2009; 143 (2): 103–6. doi: 10.1016/j.ejogrb.2008.12.010
  10. Graziano A, Lo Monte G, Piva I. Diagnostic findings in adenomyosis: A pictorial review on the major concerns. Eur Rev Med Pharmacol Sci 2015; 19 (7): 1146–54.
  11. Horton J, Sterrenburg M, Lane S et al. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. Hum Reprod Update 2019; 25 (5): 592–632. doi: 10.1093/humupd/dmz012
  12. Puente JM, Fabris A, Patel J et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol 2016; 14 (1): 60. doi: 10.1186/s12958-016-0185-6
  13. Aleksandrovych V, Bereza T, Sajewicz M et al. Uterine fibroid: Common features of widespread tumor (Review article). Folia Med Cracov 2015; 55 (1): 61–75.
  14. Kitawaki J. Adenomyosis: The pathophysiology of an oestrogen-dependent disease. Best Pract Rec Clin Obstet Gynaecol 2006; 20 (4): 493–502. doi: 10.1016/j.bpobgyn.2006.01.010
  15. Verit FF, Yucel O. Endometriosis, leiomyoma and adenomyosis: The risk of gynecologic malignancy. Asian Pac J Cancer Prev 2013; 14 (10): 5589–97. doi: 10.7314/apjcp.2013.14.10.5589
  16. Prathoomthong S, Tingthanatikul Y, Lertvikool S et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. Int J Fertil Steril 2018; 11 (4): 279–86. doi: 10.22074/ijfs.2018.5137
  17. Hricak H, Alpers C, Crooks LE et al. Magnetic resonance imaging of the female pelvis: initial experience. Am J Roentgenol 1983; 141: 1119–28. doi: 10.2214/ajr.141.6.1119
  18. Vannuccini S, Tosti C, Carmona F et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online 2017; 35: 592–601. doi: 10.1016/j.rbmo.2017.06.016
  19. Vercellini P, Bonfanti I, Berlanda N. Adenomyosis and infertility: is there a causal link? Expert Rev Endocrinol Metab 2019; 14 (6): 365–7. doi: 10.1080/17446651.2019.1697675
  20. Kang S, Zhao X, Xing H et al. Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis. Environ Mol Mutagen 2008; 49: 226–31. doi: 10.1002/em.20375
  21. Ye H, He Y, Wang J et al. Effect of matrix metalloproteinase promoter polymorphisms on endometriosis and adenomyosis risk: evidence from a meta-analysis. J Genet 2016; 95: 611–9. doi: 10.1007/s12041-016-0675-5/
  22. Bazot M, Darai E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. Fertil Steril 2018; 109: 389–97. doi: 10.1016/j.fertnstert.2018.01.024
  23. Khan KN, Fujishita A, Koshiba A et al. Biological differences between intrinsic and extrinsic adenomyosis with coexisting deep infiltrating endometriosis. Reprod Biomed Online 2019; 39 (2): 343–53.
  24. Benaglia L, Cardellicchio L, Leonardi M et al. Asymptomatic adenomyosis and embryo implantation in IVF cycles. Reprod Biomed Online 2014; 29 (5): 606–11. doi: 10.1016/j.rbmo.2014.07.021
  25. Mavrelos D, Holland TK, O’Donovan O et al. The impact of adenomyosis on the outcome of IVF-embryo transfer. Reprod Biomed Online 2017; 35 (5): 549–54. doi: 10.1016/j.rbmo.2017.06.026
  26. Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril 2017; 108 (3): 483–90.e3. doi: 10.1016/j.fertnstert.2017.06.025
  27. Sharma S, Bathwal S, Agarwal N et al. Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. Reprod Biomed Online 2019; 38 (1): 13–21. doi: 10.1016/j.rbmo.2018.09.014
  28. Vercellini P, Consonni D, Barbara G et al. Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online 2014; 28 (6): 704–13. doi: 10.1016/j.rbmo.2012.01.003/
  29. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis [version 1; referees: 2 approved] F1000Research 2019; 8: F1000 Faculty Rev–283. doi: 10.12688/f1000research.17242.1
  30. Vercellini P, Consonni D, Dridi D et al. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod 2014; 29 (5): 964–77.
  31. Савельева Г.М. Гинекология. Под ред. Г.М. Савельевой, Г.Т. Сухих, В.Н. Серова и др. М.: ГЭОТАР-Медиа, 2017. [Savelyeva G.M. Gynecology. Ed. G.M. Savelyeva, G.T. Sukhikh, V.N. Serov et al. Moscow: GEOTAR-Media, 2017 (in Russian).]
  32. Exacoustos C, Morosetti G, Conway F et al. New Sonographic Classification of Adenomyosis: Do Type and Degree of Adenomyosis Correlate to Severity of Symptoms? J Minim Invasive Gynecol 2019. doi: 10.1016/j.jmig.2019.09.788
  33. Di Donato N, Bertoldo V, Montanari G et al. Question mark form of uterus: a simple sonographic sign associated to the presence of adenomyosis. Ultrasound Obstet Gynecol 2015; 46: 126–7. doi: 10.1002/uog.14750
  34. Andres MP, Borrelli GM, Ribeiro J et al. Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. J Minim Invasive Gynecol 2018; 25 (2): 257–64. doi: 10.1016/j.jmig.2017.08.653
  35. Soave I, Wenger J, Pluchino N, Marci R. Treatment options and reproductive outcome for adenomyosis-associated infertility. Curr Med Res Opin 2018; 34 (5): 839–49. doi: 10.1080/03007995.2017.1393404
  36. Bazot M, Cortez A, Darai E et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 2001; 16: 2427–33. doi: 10.1093/humrep/16.11.2427
  37. Fedele L, Bianchi S, Frontino G. Hormonal treatments for adenomyosis. Best Pract Res Clin Obstet Gynaecol 2008; 22: 333–9. doi: 10.1016/j.bpobgyn.2007.07.006
  38. Pontis A, D’Alterio MN, Pirarba S et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol 2016; 3590: 1–5. doi: 10.1080/09513590.2016.1197200
  39. Grow DR, Filer RB. Treatment of adenomyosis with long-term GnRH analogues: A case report. Obstet Gynecol 1991; 78: 538–9.
  40. Vannuccini S, Luisi S, Tosti C et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018; 109 (3): 398–405. doi: 10.1016/j.fertnstert.2018.01.013
  41. Sasagawa S, Shimizu Y, Kami H et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008; 73: 222–31. doi: 10.1016/j.steroids.2007.10.003
  42. Takeuchi A, Koga K, Miyashita M et al. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis. Eur J Obstet Gynecol Reprod Biol 2016; 207: 157–61. doi: 10.1016/j.ejogrb.2016.10.053
  43. Khan KN, Kitajima M, Hiraki K et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010; 25 (3): 642–53. doi: 10.1093/humrep/dep437
  44. Mehasseb MK, Panchal R, Taylor AH et al. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril 2011; 95 (7): 2228–35. doi: 10.1016/j.fertnstert.2011.02.051
  45. Hirata T, Izumi G, Takamura M et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol 2014; 30: 726–9. doi: 10.3109/09513590.2014.926882
  46. Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebocontrolled study. Fertil Steril 2017; 108: 673–8. doi: 10.1016/j.fertnstert.2017.07.021
  47. Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017; 43: 1441–8. doi: 10.1111/jog.13406
  48. Nagata C, Yanagida S, Okamoto A et al. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res 2012; 38: 639–44. doi: 10.1111/j.1447-0756.2011.01778.x
  49. Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet 2015; 292: 1267–71. doi: 10.1007/s00404-015-3755-5
  50. Neriishi K, Hirata T, Fukuda S et al. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 2018; 44 (8): 1439–4. doi: 10.1111/jog.13674
  51. Harada T, Khine YM, Kaponis A et al. The Impact of Adenomyosis on Women’s Fertility. Obstet Gynecol Surv 2016; 71 (9): 557–68. doi: 10.1097/OGX.0000000000000346
  52. Rocha TP, Andres MP, Borrelli GM, Abrão MS. Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. Reprod Sci 2018; 25 (4): 480–6. doi: 10.1177/1933719118756754
  53. Стрижаков А.Н., Давыдов А.И. Миометриэктомия – метод выбора терапии больных аденомиозом в репродуктивном периоде. Акушерство и гинекология. 1995; 5: 31. [Strizhakov A.N., Davydov A.I. Miometriektomiia – metod vybora terapii bol’nykh adenomiozom v reproduktivnom periode. Akusherstvo i ginekologiia. 1995; 5: 31 (in Russian).]
  54. Wang PH, Yang TS, LeeWL et al. Treatment of infertile womenwith adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist. Fertil Steril 2000; 73: 1061–2.
  55. Коган И.Ю., Геркулов Д.А., Джемлиханова Л.Х. и др. Эффективность протоколов ЭКО у больных с тяжелой степенью эндометриоза после адъювантной терапии диеногестом. Проблемы репродукции. 2015; 21 (2): 39–44. [Kogan I.Iu., Gerkulov D.A., Dzhemlikhanova L.Kh. et al. Effektivnost’ protokolov eko u bol’nykh s tiazheloi stepen’iu endometrioza posle ad»iuvantnoi terapii dienogestom. Problemy reproduktsii. 2015; 21 (2): 39–44 (in Russian).]
  56. Hayashi A, Tanabe A, Kawabe S et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res 2012; 5: 31. doi: 10.1186/1757-2215-5-31
  57. Вартанян Э.В., Цатурова К.А., Петухова Н.Л. и др. Консервативная терапия эндометриоза при подготовке к лечению бесплодия методом экстракорпорального оплодотворения. Доктор.Ру. 2015; 1 (102): 21–5. [Vartanian E.V., Tsaturova K.A., Petukhova N.L. et al. Konservativnaia terapiia endometrioza pri podgotovke k lecheniiu besplodiia metodom ekstrakorporal’nogo oplodotvoreniia. Doktor.Ru. 2015; 1 (102): 21–5 (in Russian).]
  58. Бесплодие и эндометриоз. Версии и контраверсии. Под ред. В.Е. Радзинского, М.Р. Оразова. М.: Медиабюро Статус Презенс, 2019. [Infertility and endometriosis. Versions and contraversions. Ed. V.E. Radzinsky, M.R. Orazov. Moscow: Media Bureau Status Present, 2019 (in Russian).]



Abstract - 18

PDF (Russian) - 1





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies